DPC enters HBV market
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic Products Corp.'s hepatitis B virus test U.S. market entry Aug. 1 more than doubles the Los Angeles firm's infectious disease market potential, company says. The domestic HBV market is estimated at $300-500 mil. DPC entered the U.S. infectious disease market three years ago with tests for rubella, CMV, herpes and toxoplasmosis - a market opportunity less than half that for HBV, according to the firm. On July 31, DPC announced FDA approval of nine in vitro HBV assays for use on the Immulite and Immulite 2000 automated, chemiluminescent platforms, including two HBsAg, one HBsAg confirmatory, two Anti-HBs, two Anti-HBc and two Anti-HBc IgM tests...